
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is expected to generate positive clinical data in the next 12-18 months, providing potential upside for investors. With a strong pipeline targeting oncology and neuroscience indications, partnerships with large pharmaceutical companies, and a solid cash position, Arvinas has the potential for significant future growth and success. The company's market cap is currently hovering around $4.5 billion, with a cash runway into the second half of 2028, providing investors with a favorable entry point and potential for a meaningful return on investment.
Bears say
Arvinas is a clinical-stage biotechnology company using its PROteolysis TArgeting Chimera platform to develop therapies targeting disease-causing proteins. Despite promising preclinical data, concerns remain about the effectiveness and tolerability of its lead candidate ARV-806 compared to competitors and potential resistance mechanisms. The company also faces typical risks associated with the biotech industry, including clinical and regulatory uncertainties and competition. Additionally, while Arvinas has a strong pipeline with potential in several disease areas, its valuation may be considered high compared to its current stage of development.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares